Drug Profile
Etoricoxib - Merck & Co.
Alternative Names: Arcoxia; Exxiv; L 791456 - Merck; MK 0663; MK 663Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Merck & Co; University of Regensburg
- Class Antirheumatics; Non-opioid analgesics; Pyridines; Small molecules; Sulfones
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute pain; Ankylosing spondylitis; Back pain; Dental pain; Dysmenorrhoea; Gouty arthritis; Musculoskeletal pain; Osteoarthritis; Postoperative pain; Rheumatic disorders; Rheumatoid arthritis
- Phase III Surgical blood loss
Most Recent Events
- 13 Apr 2021 Discontinued - Phase-III for Dysmenorrhoea in China (PO)
- 22 Jan 2019 Launched for Osteoarthritis in South Korea (PO) before January 2019
- 21 Jul 2015 Discontinued - Phase-III for Ankylosing spondylitis in Canada (PO)